SCHEMBL1461384

SCHEMBL1461384

N#Cc1ccc(-n2cnc(Cl)c2Cl)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ MKNK1 Q9BUB5 1/20 0.40
▸ MKNK2 Q9HBH9 1/20 0.40
▸ GABRG2 P18507 2/20 0.39
▸ GABRB3 P28472 2/20 0.39
▸ GABRA5 P31644 2/20 0.39
▸ FLT3 P36888 1/20 0.38
▸ IRAK4 Q9NWZ3 1/20 0.38
▸ SMO Q99835 3/20 0.37
▸ GPR39 O43194 1/20 0.36
▸ PDE3B Q13370 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ PANK3 Q9H999 4/20 0.36
▸ GRM5 P41594 1/20 0.35
▸ RPS6KA5 O75582 1/20 0.35
▸ RPS6KA4 O75676 1/20 0.35
▸ CDC7 O00311 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10552778 0.72 POLB (0.55) CYP11B2KDM4EALDH1A1L3MBTL1MKNK1
SCHEMBL1460515 0.71 KDM4E (0.53) CYP11B2KDM4EALDH1A1L3MBTL1FLT3
SCHEMBL10548057 0.70 CYP11B2 (0.64) CYP11B2KDM4EALDH1A1L3MBTL1SMO
SCHEMBL3854984 0.68 CYP11B2 (0.43) CYP11B2KDM4EALDH1A1L3MBTL1GABRG2
SCHEMBL3851521 0.68 CYP11B2 (0.43) CYP11B2KDM4EALDH1A1L3MBTL1GABRG2
SCHEMBL18789238 0.68 KDM4E (0.49) CYP11B2KDM4EALDH1A1L3MBTL1FLT3
SCHEMBL21672277 0.67 CYP11B2 (0.43) CYP11B2KDM4EALDH1A1L3MBTL1SMO
SCHEMBL12825255 0.67 KDM4E (0.56) CYP11B2KDM4EALDH1A1L3MBTL1FLT3
SCHEMBL10550633 0.67 KDM4E (0.51) CYP11B2KDM4EALDH1A1L3MBTL1
SCHEMBL75830 0.67 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-04 — — US disclosed
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-04 — — US disclosed
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-04 — — US disclosed
EP-2475653-A1 SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS Bayer Pharma Aktiengesellschaft (DE) 2012-07-18 — — EP disclosed
WO-2011029537-A1 SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-03-17 — — WO disclosed
WO-2011029537-A1 SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins TPMT, BPHL, VHL CYP11B2 4/4885KDM4E 2244/4885ALDH1A1 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback